

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2023/2024 influenza season

as of September 13, 2024

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	2 (0.5%)	5 (0.5%)	5 (0.5%)	0	0	259 (100%)	4 (0.5%)	0	0	0	0	312 (100%)	0	0	0	0	0
Number of viruses tested	436	1,016	1,016	246	246	259	762	296	296	296	296	312	323	194	194	194	194
Number of viruses reported	2,078						3,636						2,067				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.